Rice students earn the most upon graduation, according to a new study. Photo courtesy of Rice University

A new study calculates that students who attend Rice University have the highest initial earning potential among Texas graduates.

Financial website SmartAsset ranked the top 10 Texas colleges where students earn the best average starting salaries upon graduation. Rice tops the list, with students earning an average of $65,700 in their first job out of school.

The salary ranking is part of a larger SmartAsset study that looked at five factors — tuition, student living costs, scholarship and grant offerings, retention rate, and starting salary — to determine the best value colleges and universities. Rice also comes in No. 1 on that list. Rice students pay an average of $42,253 tuition and $16,000 in living costs; that's offset by an average of $36,192 in scholarships and grants.

These findings come in an era where students are taking on staggering amounts of debt. The average annual growth rate for the cost to attend a four-year university between 1989 and 2016 was 2.6 percent per year, compared to a low 0.3 percent annual growth in wages, according to SmartAsset.

Another Houston-area school follows at No. 2 on the salary report. Students of The University of Texas Medical Branch in Galveston earn an average of $60,000 upon entering the workforce. (Tuition and living costs were not released for that school, nor were scholarship and grant numbers.)

Here is the breakdown of the 10 Texas schools with the highest starting salaries:

  1. Rice University, Houston, $65,700
  2. The University of Texas Medical Branch, Galveston, $60,000
  3. The University of Texas Health Science Center, San Antonio, $57,800
  4. Texas A&M University, College Station, $57,200
  5. The University of Texas, Austin, $56,900
  6. LeTourneau University, Longview, $55,300
  7. Southern Methodist University, Dallas, $55,000
  8. Prairie View A&M University, Prairie View, $54,300
  9. The University of Texas at Dallas, Richardson, $53,600
  10. Texas Tech University, Lubbock, $49,375

---

This story originally appeared on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.